News

Nyrada,Inc. Newsletter 1. Jan/Feb 2018
Noxopharm Closes $4M Capital Raising for its US Subsidiary, Nyrada,Inc.
Identification of NYX-104, a promising lead candidate for the treatment of stroke and other excitotoxicity- associated disorders.
US biotech to develop Australian science
  Subscribe to Email Alerts